HeartStitch ® Announces Expanded Intellectual Property Portfolio

Report this content

 

New Allowance of Heart Valve Suturing Patent Significantly Increases

HeartStitch’s International Intellectual Property Portfolio

 

Los Angeles, California—September 7, 2016HeartStitch® has been granted allowance of several critical new claims by the Japan Patent Office (JPO).  These claims will issue in Japan and are the latest building blocks in HeartStitch’s international strategy for remaining at the forefront of cardiac-device invention, design, and manufacture. 

 

The issuance will directly relate to the HeartStitch® AP, and the suturing of anatomic valves percutaneously.  This new technology will allow physicians to repair structural valve defects without the need for open-heart surgery. HeartStitch has already received US and other international patents for this technology and continues to strengthen its position in significant markets.

 

Prof. Anthony Nobles, Chairman of the Board and CEO of HeartStitch®, stated, “We are simply ecstatic about this announcement, and the way it solidifies HeartStitch’s ® international intellectual-property foundation.  As a company that’s so focused on innovation and next-generation solutions, protection of our ideas is essential.  Protection in a single market is just not sufficient in a global marketplace, so you must make your arguments multiple times, and on many continents.  Getting the protection your company and its investor’s need is a significant skill, and we’ve spent a lot of time and effort securing the right people with the right talents.  As we continue to roll out more and more products in the year to come, we’ll be leveraging their capabilities more often, and in more locations.”

 

Dr. Kanat Baigarin, Vice President for Innovation & Research at Nazarbayev University and

Member of the HeartStitch® Board of Directors commented, “The Asian markets are very important to our international presence in the cardiac market. We continue to expand globally our technology and intellectual property is critical to the success of a medical device. Without that protection these life saving technologies would not make it to the market and the patients that need them. I personally am very proud to be a part of this effort and continue to support our engineers and staff that invent these valuable new technologies.

Prof. Anthony Nobles founded HeartStitch® Inc. with the intent of leveraging its technologies in the structural heart marketplace.  HeartStitch® is focused on innovative suture-based systems for remotely providing suture repair of structural heart defects and other vascular structures.

 

For more information, please contact shareholder representatives:

 

USA

Dru Dobbs

P. +1 714 427 6348

F. +1 714 427 6343

ddobbs@HeartStitch.com

 

 

In Kazakhstan

Kazbek Aubakirov

P. +7 777 5009005

kaubakirov@HeartStitch.com

 

About HeartStitch®

HeartStitch® Inc. was founded by Prof. Anthony Nobles with the intent of leveraging its technologies in the structural heart marketplace.  HeartStitch® is focused on innovative suture-based systems for remotely providing suture repair of structural heart defects and other vascular structures.

 

The HeartStitch® TA and HeartStitch® MR are FDA cleared for vascular suturing in the United States.  HeartStitch® manufactures and markets the NobleStitch™ EL under exclusive license from Nobles ​Medical technologies II, Inc.  NobleStitch™ EL is FDA cleared for vascular suturing in the United States and CE Marked for cardio-vascular suturing and PFO closure in the European Union and the Republic of Kazakhstan, respectively.

 

HeartStitch® is a registered trademark of HeartStitch, Inc.

 

HeartStitch® TA for cardiac suturing and transapical access and closure

Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8348962, 8469975, 8496676, and 8709020.

 

HeartStitch® MR for suturing an anatomical valve

Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8348962, 8469975, 8496676, 8709020, and 8771296.

 

NobleStitch™ EL for PFO closure

Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8197510, 8246636, 8348962, 8372089, 8469975, 8496676, 8709020, and 9131938.

 

For more on HeartStitch® visit http://www.heartstitch.com

Tags:

Media

Media